News | Artificial Intelligence | February 23, 2021

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

icobrain cva allows the quantitative assessment of tissue perfusion by reporting the volume of core and perfusion lesion by quantifying Tmax abnormality and CBF abnormality together with the mismatch volume and ratio

February 23, 2021 — icometrix, world leader in imaging artificial intelligence (AI) solutions for people with neurological conditions, announced the addition of icobrain cva, a stroke solution, to the icobrain portfolio. The announcement follows the FDA-clearance and CE-marking of its image processing software for the analysis and communication of the tissue perfusion state on computed tomography (CT) perfusion scans in patients with ischemic stroke. icobrain cva provides physicians with fast, fully automated, and state-of-the-art insights to support treatment decisions in acute ischemic stroke.

Since 2018, treatment guidelines for stroke have expanded the treatment window for mechanical thrombectomy from 6 to 24 hours. Treatment for ischemic stroke is not without risk and requires careful patient selection based on their tissue status. The automated assessment of tissue parameters in an acute clinical setting by icobrain cva will allow more patients to get the right treatment and can improve patient outcomes and care while increasing efficiency.

"With the launch of icobrain cva we address a persisting need in the treatment of acute ischemic stroke. By democratizing advanced CT perfusion analysis for healthcare systems worldwide we take the next step in our mission to become a holistic brain solution provider," said Wim Van Hecke, CEO at icometrix.

"The main challenge of current stroke solutions is correctly identifying the entry point of the injected contrast in the brain. icobrain cva introduces new, patented, deep learning technology into this identification process to achieve a more robust assessment of the infarcted area," explained Dirk Smeets, CTO at icometrix.

icobrain cva is a fully-automated CE-marked and FDA-cleared software solution for the quantitative assessment of tissue perfusion on CT. icobrain cva reports the volume of the core and perfusion lesion by quantifying reduced cerebral blood flow, volume, and transit time. The report includes information on the correctness of the selected arterial input function and the quality of the output. icobrain cva is a cloud-based solution, returning a report and perfusion maps straight into your PACS and e-mail inbox.

For more information: icometrix.com


Related Content

News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
News | ASE

May 4, 2026 — The American Society of Echocardiography (ASE) has released a new guideline that provides guidance for ...

Time May 05, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

April 27 2026 — SimonMed, one of the nation’s largest independent outpatient imaging providers, has announced the ...

Time May 04, 2026
arrow
News | Women's Health

May 1, 2026 — Women’s health services face rising complexity with growing patient volumes across fertility care ...

Time May 01, 2026
arrow
Feature | Information Technology

AT A GLANCE Organization: Expert Radiology Management Services, LLC Specialty: Subspecialty teleradiology — neuro and ...

Time May 01, 2026
arrow
News | X-Ray

April 29, 2026 — Results from a new study* presented at the American Roentgen Ray Society’s (ARRS) 2026 annual meeting ...

Time April 29, 2026
arrow
News | Imaging Software Development

April 28, 2026 — Avatar Medical has been granted FDA 510(k) clearance for Avatar Medical Vision, its software platform ...

Time April 28, 2026
arrow
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Time April 28, 2026
arrow
News | Artificial Intelligence

April 20, 2026 — DeepTek, provider of the Augmento platform and deepc, the company behind deepcOS, have introduced a ...

Time April 23, 2026
arrow
News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
Subscribe Now